CASE STUDY

Selective Extraction In Method Development

Selective Extraction In Method Development

Background

A Pharmaceutical Company was finding higher than expected plasma drug concentrations during a Phase I study for a chemotherapeutic prodrug and suspected that in vitro conversion of the prodrug to the drug might be the cause.

The Challenge

The assay employed by the Client was for the analysis of all three substances (the prodrug, drug, and a metabolite) simultaneously. This process was leading to the conversion of the prodrug to the drug during the extraction process and elevating the measured drug concentrations.

The Solution

Our scientists carefully studied the solubility of each substance and developed a new assay which first selectively extracted the drug (formed in vivo) from plasma as soon as it was thawed leaving the prodrug and metabolite behind. The drug was then quantified by an LC/MS/MS system, while the prodrug and the metabolite were extracted separately from the plasma samples and analyzed by a HPLC-fluorescence system. This selective extraction process enabled the accurate determination of the in vivo drug concentration.

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.